Keith Ligon is a principal investigator and board-certified Neuropathologist with expertise in glioma research. He holds joint appointments at the Dana-Farber Cancer Institute, Brigham and Women’s Hospital, Boston Children’s Hospital, and the Broad Institute. His early work demonstrated the essential role of OLIG2 in cancer stem-like cells of glioblastoma and medulloblastoma (Schuller U. et. Al. Cancer Cell 2008). His lab recently identified MYB-family transcription factors as new driver oncogenes in pediatric astrocytomas and elucidated their biological and epigenetic effects (Ramkissoon LA. et al PNAS 2013, Bandopadhayay P, et al Nat Gen 2016). He has made essential contributions in diagnostics and targeted therapy of gliomas (Francis J. et. Al. Cancer Discovery 2013). His lab has focused on generation and investigation of patient derived models of glioma and has generated more than 1000 patient models of brain cancers and has utilized these for preclinical studies of novel therapies. He serves as PI of one NCI R01 focused on glioma responses to therapy. He directs NCI P01 and P50 (SPORE) Pathology Cores and act as the PI of the unified Neurooncology Tissue and Data Bank across 4 member institutions of the P30 NCI designated Dana-Farber Harvard Cancer Center. He also has leadership roles and participation in pathology and biomarker research within several national NCI sponsored and private clinical trial consortia (DIPG-BATS, PNOC, COG, ABTC, Alliance, Ivy Foundation).